TOSS, ANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.111
AS - Asia 8.623
EU - Europa 6.426
SA - Sud America 1.371
Continente sconosciuto - Info sul continente non disponibili 293
AF - Africa 268
OC - Oceania 56
Totale 34.148
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.477
SG - Singapore 2.467
IT - Italia 2.015
CN - Cina 2.011
GB - Regno Unito 1.135
VN - Vietnam 1.074
BR - Brasile 1.002
HK - Hong Kong 991
DE - Germania 587
SE - Svezia 557
BD - Bangladesh 514
IE - Irlanda 342
FI - Finlandia 332
RU - Federazione Russa 329
CA - Canada 301
KR - Corea 278
FR - Francia 272
IN - India 250
ID - Indonesia 197
TR - Turchia 132
UA - Ucraina 130
AR - Argentina 117
MX - Messico 114
NL - Olanda 113
JP - Giappone 108
IQ - Iraq 98
BG - Bulgaria 96
ES - Italia 83
PL - Polonia 74
ZA - Sudafrica 68
EC - Ecuador 64
LT - Lituania 64
CO - Colombia 61
PK - Pakistan 59
MY - Malesia 53
AU - Australia 51
EG - Egitto 49
TW - Taiwan 45
AT - Austria 44
CR - Costa Rica 43
AE - Emirati Arabi Uniti 40
VE - Venezuela 38
MA - Marocco 35
IR - Iran 32
PH - Filippine 32
SA - Arabia Saudita 32
CL - Cile 31
BE - Belgio 29
UZ - Uzbekistan 28
KE - Kenya 26
PY - Paraguay 24
HN - Honduras 22
SV - El Salvador 21
CZ - Repubblica Ceca 20
IL - Israele 20
JM - Giamaica 20
JO - Giordania 20
NP - Nepal 20
PR - Porto Rico 20
TH - Thailandia 18
AZ - Azerbaigian 17
DK - Danimarca 17
NO - Norvegia 17
GT - Guatemala 16
HU - Ungheria 16
TN - Tunisia 16
MD - Moldavia 15
SI - Slovenia 15
TT - Trinidad e Tobago 15
BO - Bolivia 14
CH - Svizzera 14
CW - ???statistics.table.value.countryCode.CW??? 14
GR - Grecia 14
AL - Albania 13
DZ - Algeria 12
GP - Guadalupe 12
NI - Nicaragua 12
PA - Panama 12
RO - Romania 12
PE - Perù 11
DO - Repubblica Dominicana 10
HR - Croazia 10
RS - Serbia 10
SY - Repubblica araba siriana 10
KG - Kirghizistan 9
CI - Costa d'Avorio 8
KZ - Kazakistan 8
LB - Libano 8
LV - Lettonia 8
MT - Malta 8
OM - Oman 8
PT - Portogallo 8
BY - Bielorussia 7
CY - Cipro 7
ET - Etiopia 7
UY - Uruguay 7
AO - Angola 6
BH - Bahrain 6
GE - Georgia 6
SC - Seychelles 6
Totale 33.766
Salva come PNG Salva come JPEG
Città #
Ashburn 2.307
Singapore 1.433
Santa Clara 1.428
Fairfield 1.115
San Jose 1.101
Hong Kong 960
Chandler 751
Council Bluffs 742
Hefei 669
Woodbridge 537
Seattle 482
Houston 443
Southend 395
Cambridge 391
Beijing 371
Ho Chi Minh City 343
Dublin 338
London 337
Nyköping 336
Wilmington 335
Los Angeles 323
Dallas 304
New York 285
Helsinki 260
Seoul 259
Hanoi 251
Chicago 233
Milan 216
Dearborn 212
Modena 211
Ann Arbor 206
The Dalles 169
Jakarta 138
Lauterbourg 123
Boardman 114
Bologna 114
San Diego 110
Jacksonville 109
Princeton 100
São Paulo 99
Buffalo 95
Rome 94
Tokyo 91
Munich 90
Sofia 90
Moscow 89
Shanghai 79
Frankfurt am Main 77
Orem 75
Phoenix 70
Salt Lake City 69
Toronto 61
Bremen 58
Atlanta 53
Eugene 53
Redwood City 53
Warsaw 53
Izmir 52
Montreal 52
Baghdad 51
Columbus 51
Da Nang 51
Haiphong 50
Brooklyn 48
Denver 48
North Bergen 48
Fremont 44
Manchester 44
Naples 44
Nuremberg 44
Reggio Emilia 41
Kent 39
Dong Ket 38
Guangzhou 38
Mexico City 37
Johannesburg 36
Miami 36
Chennai 34
Portsmouth 33
Rio de Janeiro 33
Florence 32
Philadelphia 32
San José 32
Stockholm 32
Belo Horizonte 31
Lappeenranta 31
Parma 31
Redondo Beach 31
Mumbai 30
Boston 29
Las Vegas 28
San Giuliano Milanese 28
Dhaka 27
Düsseldorf 27
Poplar 27
Turin 27
Brasília 26
Falls Church 26
Turku 26
Madrid 25
Totale 21.470
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 657
A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women 505
Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma 493
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 482
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 454
Abstracts from the 55th European Society of Human Genetics (ESHG) Conference: Hybrid Posters 445
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 424
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 419
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 385
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 383
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 380
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 379
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? 372
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 370
Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer 363
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 354
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 352
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 347
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 342
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 336
NUT midline carcinoma of the head and neck: current perspectives 331
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 327
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers 326
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 324
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study 323
Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study 317
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 316
CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY 316
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes 315
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 306
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 306
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life 305
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 305
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 304
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 303
PARP Inhibitors for Breast Cancer Treatment A Review 296
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 295
Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the modena familial breast and ovarian cancer center (Italy) 292
Hereditary ovarian cancers: State of the art 292
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 291
Combined hormonal contraceptives in BRCA gene mutation carriers: why not? 279
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 275
Chemoprevention strategies in hereditary breast and ovarian cancer syndromes 274
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 274
Characterization of new ATM deletion associated with hereditary breast cancer 272
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 270
The role of exosomes in breast cancer diagnosis 270
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 269
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 269
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 266
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification 265
Carboplatin-paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosis 264
Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores 263
Chemoprevention strategies for high risk women 263
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women with Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial 263
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 260
Twenty-years experience with de novo metastatic breast cancer 258
Male Bilateral Risk-Reducing Mastectomy: Report of a Case 258
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 258
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 254
Radiological screening programs for women at high risk of developing breast cancer 252
Relative and disease-free survival for breast cancer in relation to subtype: a population-based study 248
Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study 246
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 243
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 242
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 240
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 240
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 238
Molecular characterization and targeted therapeutic approaches in breast cancer 237
Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness 237
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 233
Breast ultrasound in high-risk women 232
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 228
BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study 228
The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: A prospective cohort, other biomarker controlled, study 226
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 222
PARP inhibitors for the treatment of ovarian cancer 221
Management of PALB2-associated breast cancer: A literature review and case report 211
Obesity in Postmenopausal Breast Cancer Patients: It Is Time to Improve Actions for a Healthier Lifestyle. The Results of a Comparison Between Two Italian Regions With Different “Presumed” Lifestyles 209
Personalized Systemic Therapies in Hereditary Cancer Syndromes 208
Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report 205
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 204
Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk 203
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores 202
Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less 200
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer 198
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour 195
The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance 195
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study 193
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees 193
Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group 192
Correction to: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (npj Breast Cancer, (2024), 10, 1, (58), 10.1038/s41523-024-00657-z) 191
COVID-related disruption in mammographic screening: a year later. 191
DCE-MRI Radiomic analysis in triple negative ductal invasive breast cancer. Comparison between BRCA and not BRCA mutated patients: Preliminary results 191
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 190
Occult breast cancer: the uncommon presentation of a common disease 190
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA) 187
The spectrum of fancm protein truncating variants in European breast cancer cases 185
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 184
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe 179
Totale 28.265
Salva come PNG Salva come JPEG
Categoria #
all - tutte 133.434
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 133.434
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.377 0 0 0 0 68 133 90 102 250 164 336 234
2022/20232.396 268 301 169 192 225 259 48 180 526 35 98 95
2023/20241.756 92 92 97 175 260 144 230 229 68 69 114 186
2024/20255.933 141 59 120 302 986 765 584 372 703 389 644 868
2025/202612.860 900 476 1.134 1.391 1.504 824 1.575 708 1.232 1.257 1.077 782
2026/20274.183 495 839 1.081 1.542 226 0 0 0 0 0 0 0
Totale 34.148